Home > Insider Trading > Filing (0001399529-20-000094)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	205993609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598479	D Bob Brown	C/O Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington MA 02421	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-12-01	8,185	$3.42	34,702	No	4	M	Direct
Common Stock	Disposition	2020-12-01	8,185	$25.19	26,517	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-12-01	8,185	$0.00	8,185	$3.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2023-09-24	No	4	M	Direct

Footnotes

The Reporting Person sold an aggregate of 8,185 shares of common stock on December 1, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.87% of 940,402 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2019.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.88 to $25.60, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The vesting of these options was subject to achievement of pre-established performance goals. As of the transaction date, the options were fully vested.